Recent advances towards identification of new drug targets for Mycobacterium tuberculosis

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 2, 2004, Pages 79-93

  Sharma, Kirti ^a   Chopra, Puneet ^a   Singh, Yogendra ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

factors; Cell wall; Chemotherapy; Drug targets; Kinases; Myobacterium; Persistence; Phosphatases; Tuberculosis

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; ACYL CARRIER PROTEIN; ALANINE RACEMASE; AMIKACIN; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CYCLOSERINE; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHAMBUTOL; ETHIONAMIDE; FASUDIL; FATTY ACID SYNTHASE; FOLIC ACID; IMATINIB; ISOCITRATE LYASE; ISONIAZID; KANAMYCIN; MYCOLIC ACID; OXIDOREDUCTASE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STIBOGLUCONATE SODIUM; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

BACTERIAL CELL WALL; BACTERIAL GENOME; BACTERIAL VIRULENCE; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENERGY METABOLISM; GENE SEQUENCE; HUMAN; LEISHMANIASIS; MOLECULAR MECHANICS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 1842843660     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.2.79     Document Type: Review

References (114)

1. SNIDER DE Jr, RAVIGLIONE M, KOCHI A: Tuberculosis: pathogenesis, protection, and control. Bloom BR (Ed.), American Society for Microbiology, Washington DC, USA (1994):2-11.
2. KOCHI A: WHO report on the tuberculosis epidemic (1996).
3. CULLITON BJ: Drug-resistant TB may bring epidemic. Nature (1992) 356:473. Erratum 737.
4. STURGILL-KOSZYCKI S, SCHLESINGER PH, CHAKRABORTY P et al.: Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science (1994) 263:678-681.
5. ARMSTRONG JA, HART PD: Phagosome-lysosome interaction in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual non-fusion pattern and observation on bactericidal survival. J. Exp. Med. (1975) 142:1-16.
6. NOSS EH, HARDING CV, BOOM WH: Mycobacterium tuberculosis inhibits MHC Class II antigen processing in murine bone marrow macrophages. Cell. Immunol. (2000) 201:63-74.
7. FERRARI G, LANGEN H, NAITO M, PIETERS J: A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell (1999) 97:435-447.
8. GHOSH S, PAL S, DAS S, DASGUPTA SK, MAJUMDAR S: Lipoarabinomannan induced cytotoxic effects in human mononuclear cells. FEMS Immunol. Med. Microbiol. (1998) 21:181-188.
9. ZAHRT TC: Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. Microbes Infect. (2003) 5:159-167.
10. WINDER G, COLLINS PB: Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol. (1970) 63:41-48.
11. BANERJEE A, DUBNAU E, QUEMARD A et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 263:227-230.
12. TELENTI A, IMBODEN P, MARCHESI F, LOWRIE D, COLE S, COLSTON MJ: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 341:647-650.
13. ZIMHONY O, COX JS, WELCH JT, VILCHEZE C, JACOBS WR Jr: Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. (2000) 6:1043-1047.
14. TAKAYAMA K, KILBURN JO: Inhibition of synthesis of arabinogalactan by ethambutol in Mycobarterium smegmatis. Antimicrob. Agents Chemother. (1989) 33:1493-1499.
15. WINDER FG: The antibacterial action of streptomycin, isoniazid and PAS. In: Chemotherapy of tuberculosis. Barry VC (Ed.), Butterworth & Co. Ltd, London, UK (1964):111-149.
16. ZHANG Y, TELENTI A. In: Molecular Genetics of mycobacteria. Hatfull GF, Jacobs WR Jr (Eds), ASM Press, Washington DC, USA (2000):235-254.
17. RANDO RR: On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors. Biochem. Pharmacol. (1975) 24:1153-1160.
18. JACOBS MR: Activity of quinolones against mycobacteria. Drugs (1995) 58:19-22.
19. GILLESPIE SH: Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. (2002) 46:267-274.
20. WORLD HEALTH ORGANIZATION: Tuberculosis Fact Sheet (No. 104) 2000.
21. SNIDER DE JR, CASTRO KG: The global threat of drug-resistant tuberculosis. N. Engl. J. Med. (1998) 338:1689-1690.
22. MAHMOUDI A, ISEMAN MD: Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA (1993) 270:65-68.
23. ZHANG Y, MARIO AL: Tuberculosis drug targets. Curr. Drug Targets (2002) 3:131-154.
24. COLE ST, BROSCH R, PARKHILL J et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393:537-544
25. SASSETTI CM, BOYD D H, RUBIN EJ: Genes required for mycobacterial growth defined by high-density mutagenesis. Mol. Microbiol. (2003) 48:77-84.
26. BUCHMEIER N, BLANC-POTARD A, EHRT S, PIDDINGTON D, RILEY L, GROISMAN EA: A parallel intraphagosomal survival strategy shared by Mycobacterium tuberculosis and Salmonella enterica. Mol. Microbiol. (2000) 35:1375-1382.
27. GOLD B, RODRIGUEZ GM, MARRAS SA, PENTECOST M, SMITH I: The Myrobacterium tuberculosis IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. Mol. Microbiol. (2001) 42:851-865.
28. DE VOSS JJ, RUTTER K, SCHROEDER BG, SU H, ZHU Y, BARRY CE III: The salicylate-derived mycobactein siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. USA (2000) 97:1252-1257.
29. HONDALUS MK, BARDAROV S, RUSSELL R, CHAN J, JACOBS WR Jr, BLOOM BR: Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. (2000) 68:2888-2898.
30. PAVELKA MS Jr, CHEN B, KELLEY CL, COLLINS FM, JACOBS WR Jr: Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect. Immun. (2003) 71:4190-4192.
31. SMITH DA, PARISH T, STOKER NG, BANCROFT GJ: Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. (2001) 69:1142-1150.
32. JACKSON M, PHALEN SW, LAGRANDERIE M et al.: Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. (1999) 67-2867-2873.
33. PEREIRA JH, CANDURI F, DE OLIVEIRA JS, DA SILVEIRA NJ, BASSO LA, PALMA MS: Structural bioinformatics study of EPSP synthase from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. (2003) 312:608-614.
34. SAMBANDAMURTHY VK, WANG X, CHEN B et al.: A pantothenate auxotrophs of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. (2002) 8:1171-1174.
35. HUOVINEN P, SUNDSTROM L, SWEDBERG G, SKOLD O: Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. (1995) 39:279-289.
36. LOCHER HH, SCHLUNEGGER H, HARTMAN PG, ANGEHRN P, THEN RL: Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob. Agents Chemother. (1996) 40:1376-1381.
37. GLICKMANN MS: A novel mycolic acid cyclopropane synthetase is required for cording, persistance and virulence of Mycobacterium tuberculosis. Mol. Cell. (2000) 5:717-727.
38. MCKINNEY JD, HONER ZU BENTRUP K, MUNOZ-ELLAS EJ et al.: Persistance of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 406:735-738.
39. RAYNAUD C, GUILHOT C, RAUZIER J et al.: Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Mol. Microbiol. (2002) 45:203-217.
40. BOSHOFF HI, REED MB, BARRY CE III, MIZRAHI V: DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacierium tuberculosis. Cell (2003) 113:183-193.
41. DAHL JL, KRAUS CN, BOSHOFF HI et al.: The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl. Acad. Sci. USA (2003) 100:10026-10031.
42. SUN Z, ZHANG Y: Spent culture supernatant of Mycobacterium tuberculosis H37Ra improves viability of aged cultures of this strain and allows small inocula to initiate growth. J. Bacteriol. (1999) 181:7626-7628.
43. ZHANG Y, YANG Y, WOODS A et al.: Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem. Biophys. Res. Commun. (2001) 284:542-547.
44. MUKAMOLOVA GV, KAPRELYANTS AS, YOUNG DI et al.: A bacterial cytokine. Proc. Natl. Acad. Sci. USA (1998) 95:8916-8921.
45. CHOPRA P, MEENA LS, SINGH Y: New drug targets of Mycobacterium tuberculosis. Indian J. Med. Res. (2003) 117:1-9.
46. COHEN P: Protein kinases - the major drug targets of the twenty-first century? Nat. Pev. Drug Discou (2002) 1:309-315.
47. LYON MA, DUCRUET AP, WIPF P, LAZO JS: Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. (2002) 1:961-976.
48. VAN HUIJSDUIJNEN RH, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013-1019.
49. MCCLUSKEY A, SAKOFF JA: Small molecule inhibitors of serine/threonine protein phosphatases. Mini Rev. Med. Chem. (2001) 1:43-55.
50. HUIJSDUIJNEN RHV, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013-1019.
51. PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. (2001) 167:3391-3397.
52. AV-GAY Y, EVERETT M: The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol. (2000) 8:234-244.
53. HAKANSSON SE, GALYOV EE, ROSQVIST R, WOLF-WATZ H: The Yersinia YpkA Ser/Thr kinase is translocated into and subsequently targeted to the inner surface of the Hela cell plasma membrane. Mol. Microbiol. (1996) 20:593-603.
54. DREWS S J, HUNG F, AV-GAY Y: A protein kinase inhibitor as an antibacterial agent. FEMS Microbiol. Lett. (2001) 205:369-374.
55. CHABA R, RAJE M, CHAKRABARTY PK: Evidences that a eukaryotic-type serine/threonine protein kinase from Mycobacterium tuberculosis regulates morphological changes associated with cell division. Eur. J. Biochem. (2002) 269:1078-1085.
56. ORTIZ-LOMBARDÍA M, POMPEO F, BOITEL B, ALZARI PM: Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis. J. Biol. Chem. (2003) 278:13094-13100.
57. YOUNG TA, DELAGOUTTE B, ENDRIZZI JA, FALICK AM, ALBER T: Structure of Mycobaterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nat. Struct. Biol. (2003) 10:168-174.
58. AV-GAY Y, JAMIL S, DREWS SJ: Expression and characterization of the Mycobacterium tuberculosis serine/threonine protein kinase PknB. Infect. Immun. (1999) 67:5676-5682.
59. KOUL A, CHOIDAS A, TYAGI AK et al.: Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. Microbiology (2001) 147:2307-2314.
60. SHARMA K, CHANDRA H, GUPTA PK et al.: PknH, a transmembrane Hank's type serine/threonine kinase from Mycobacterium tuberculosis is differentially expressed under stress conditions. FEMS Microbiol. Lett. (2004). In Press.
61. MOLLE V, KREMER L, GIRARD-BLANC C, BESRA GS, COZZONE AJ, PROST JF: An FHA phosphoprotein recognition domain mediates protein EmbR phosphorylation by PknH, a Ser/Thr protein kinase from Mycobacterium tuberculosis. Biochemistry (Mosc.) (2003) 42:15300-15309.
62. COWLEY SC, AV-GAY Y: Promoter activity and protein localization in Mycobacterium spp. using green fluorescent protein. Gene (2001) 264:225-231.
63. AGARWAL N, TYAGI AK: Role of 5′-TGN-3′ motif in the interaction of mycobacterial RNA polymerase with a promoter of 'extended-10' class. FEMS Microbiol. Lett. (2003) 225:75-83.
64. BERT KLEBL: Target driven drug discovery in TB, employing the mycobacterial kinase PknG. Gordon Research Conference on Tuberculosis Drug Discovery. Oxford, UK (2003).
65. FU Y, GALAN JE: A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host cell recovery after bacterial invasion. Nature (1999) 401:293-297.
66. BLISKA JB, GUAN K, DIXON JE, FALKOW S: Tyrosine phosphatase hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci USA (1991) 88:1187-1191.
67. KUSNER DJ, HALL CF, SCHLESINGER LS: Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. J. Exp. Med. (1996) 184:585-595.
68. DE CAMILLI P, EMR SD, MCPHERSON PS, NOVICK P: Phosphoinositides as regulators of membrane traffic. Science (1996) 271:1533-1539.
69. 2+ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. J. Immunol. (2003) 170:2811-2815.
70. HESTVIK AL, HMAMA Z, AV-GAY Y: Kinome analysis of host response to mycobacterial infection: a novel technique in proteomics. Infect. Immun. (2003) 71:5514-5522.
71. 2+/calmodulin-PI3K hVPS34 cascade. J. Exp. Med. (2003) 198:653-659.
72. SINGH B, SINGH G, TRAJKOVIC V, SHARMA P: Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release. Clin. Exp. Immunol. (2003) 134:70-77.
73. KOUL A, CHOIDAS A, TREDER M et al.: Cloning and characterization of secretory tyrosine phosphatase of Mycobacterium tuberculosis. J. Bacteriol. (2000) 182:5425-5432.
74. SINGH R, RAO V, SHAKILA H et al.: Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol. Microbiol. (2003) 50:751-762.
75. COWLEY SC, BABAKAIFF R, AV-GAY Y: Expression and localization of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Res. Microbiol. (2002) 153:233-241.
76. CHOPRA P, SINGH B, SINGH R et al.: Phosphoprotein phosphatase of Myrobacterium tuberculosis dephosphorylates serine-threonine kinases PknA and PknB. Biochem. Biophys. Res. Commun. (2003) 311:112-120.
77. BOITEL B, ORTIZ-LOMBARDÍA M, DURÁN R et al.: PknB kinase activity is regulated by phosphorylation in two Thr residues and dephosphorylation by Pstp, the cognate phospho-Ser/Thr phosphatase, in Mycobacterium tuberculosis. Mol. Microbiol. (2003) 49:1493-1508.
78. HOCH JA: Two-component and phosphorelay signal transduction. Curr. Opin. Microbiol. (2000) 3:165-170.
79. PARISH T, SMITH DA, KENDALL S, CASALI N, BANCROFT GJ, STOKER NG: Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect. Immun. (2003) 71:1134-1140.
80. PEREZ E, SAMPER S, BORDAS Y, GUILHOT C, GICQUEL B, MARTIN C: An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol. (2001) 41:179-187.
81. ZAHRT TC, DERETIC V: An essential two-component signal transduction system in Mycobacterium tuberculosis. J. Bacteriol. (2000) 182:3832-3838.
82. DASGUPTA N, KAPUR V, SINGH KK et al.: Characterization of a two-component system, devR-devS, of Mycobacterium tuberculosis. Tuber. Lung Dis. (2000) 80:141-159.
83. GLICKMAN MS, JACOBS WB Jr: Microbial pathogenesis of Mycobacterium tuberculosis; dawn of a discipline. Cell (2001) 104:477-485.
84. NIEDERWEIS M: Mycobacterial porins - new channel proteins in unique outer membranes. Mol. Microbiol. (2003) 49:1167-1177.
85. DEVERGNE O, EMILIE D, PEUCHMAUR M, CREVON MC, DÍAGAY MF, GALANAUD P: Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1-β and interferon-γ genes. Hum. Pathol. (1992) 23:317-323.
86. CHAN J, RAN X, HUNTER SW, BRENNAN PJ, BLOOM BR: Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. (1991) 59:1755-1761.
87. BERTHET FX, LAGRANDERIE M, GOUNON P et al.: Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science (1998) 282:759-762.
88. COX JS, CHEN B, MCNEIL M, JACOBS WR Jr: Complex lipid determines tissue specific replication of Mycobacterium tuberculosis in mice. Nature (1999) 402:79-83.
89. DUBNAU E, CHAN J, RAYNAUD C et al.: Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. (2000) 36:630-637.
90. MA Y, STERN RJ, SCHERMAN MS et al.: Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother. (2001) 45:1407-1416.
91. HOU JY, GRAHAM JE, CLARK-CURTISS JE: Mycobacterium avium genes expressed during growth in human macrophages detected by selective capture of transcribed sequences (SCOTS). Infect. Immun. (2002) 70:3714-3726.
92. CHAKRABARTY AM: Nucleoside diphosphate kinase: role in bacterial growth, virulence, cell signalling and polysaccharide synthesis. Mol. Microbiol. (1998) 28:875-882.
93. CHOPRA P, SINGH A, KOUL A et al.: Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis. Eur. J. Biochem. (2003) 270:625-634.
94. COLLINS DM, KAWAKAMI RP, DE LISLE GW, PASCOPELLA L, BLOOM BR, JACOBS WR Jr: Mutation of the principal σ factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. USA (1995) 92:8036-8040.
95. STEYN AJ, COLLINS DM, HONDALUS MK, JACOBS WR Jr, KAWAKAMI RP, BLOOM BR: Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc. Natl. Acad. Sci. USA (2002) 99:3147-3152.
96. CHEN P, RAFAEL E, RUIZ QING LI, RICHARD FS, BISHAI WR: Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate σ factor gene, sigF. Infect. Immun. (2000) 68:5575-5580.
97. DOUKHAN L, PREDICH M, NAIR G et al.: Genomic organization of the mycobacterial σ gene cluster. Gene (1995) 165:67-70.
98. WU QL, KONG D, LAM K, HUSSON RN: A mycobacterial extracytoplasmic function σ factor involved in survival following stress. J. Bacteriol. (1997) 179:2922-2929.
99. RAMAN S, SONG T, PUYANG X, BARDAROV S, JACOBS WR Jr, HUSSON RN: The alternative σ factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J. Bacteriol. (2001) 183:6119-6125.
100. SAREEN D, NEWTON GL, FAHEY RC, BUCHMEIER NA: Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. J. Bacteriol. (2003) 185:6736-6740.
101. BANU S, HONORE N, SAINT-JOANIS B, PHILPOTT D, PREVOST MC, COLE ST: Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol. Microbiol. (2002) 44:9-19.
102. BRENNAN MJ, DELOGU G, CHEN Y et al.: Evidence that mycobacterial PE-PGRS proteins are cell surface constituents that influence interactions with other cells. Infect. Immun. (2001) 69:7326-7333.
103. DELOGU G, BRENNAN MJ: Comparative immune response to PE and PE-PGRS antigens of Mycobacterium tuberculosis. Infect. Immun. (2001) 69:5606-5611.
104. SINGH KK, ZHANG X, PATIBANDLA AS, CHIEN P Jr, LAAL S: Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect. Immun. (2001) 69:4185-4191.
105. RAMAKRISHNAN L, FEDERSPIEL NA, FALKO WS: Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science (2000) 288:1436-1439.
106. COLE ST: Learning ftom the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett. (1999) 452:7-10.
107. FLORES J, ESPITIA C: Differential expression of PE and PE-PGRS genes in Mycobacterium tuberculosis strains. Gene (2003) 318:75-81.
108. LI Z, KELLEY C, COLLINS F, ROUSE D, MORRIS S: Expression of katG in Myrobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J. Infect. Dis. (1998) 177:1030-1035.
109. EDWARDS KM, CYNAMON MH, VOLADRI RK et al.: Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. (2001) 164:2213-2219.
110. SKJOT RLV, OETTINGER T, ROSWNKRANDS I et al.: Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. (2000) 68:214-220.
111. WARDS BJ, DE LISLE GW, COLLINS DM: An esat6 knockout mutant of Mycobacteriwn bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine. Tuber. Lung Dis. (2000) 80:185-189.
112. COPP BR: Antimycobacterial natural products: Nat. Prod. Rep. (2003) 20:535-557.
113. NEWTON SM, LAU C, WRIGHT CW: A review of antimycobacterial natural products. Phytother. Res. (2000) 14:303-322.
114. NCAYIYANA DJ: Africa can solve its own health problems. Br. Med. J. (2002) 324:688-689.